A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
-
Adult
-
Adult
-
Aged
-
Aged
-
Angiogenesis Inhibitors
-
Angiogenesis Inhibitors
-
Antigens, CD
-
Antigens, CD
-
Biomarkers, Tumor
-
Biomarkers, Tumor
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Endothelial Protein C Receptor
-
Endothelial Protein C Receptor
-
Female
-
Female
-
Fibroblast Growth Factor 2
-
Fibroblast Growth Factor 2
-
Humans
-
Humans
-
Leiomyosarcoma
-
Leiomyosarcoma
-
Middle Aged
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Neoplasm Recurrence, Local
-
Neovascularization, Pathologic
-
Neovascularization, Pathologic
-
Proportional Hazards Models
-
Proportional Hazards Models
-
Receptors, Cell Surface
-
Receptors, Cell Surface
-
Thalidomide
-
Thalidomide
-
Uterine Neoplasms
-
Uterine Neoplasms
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factor A